Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.42 |
| ▸ | NPC1 | O15118 | 2/20 | 0.39 |
| ▸ | RAB9A | P51151 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 2/20 | 0.38 |
| ▸ | PDE2A | O00408 | 1/20 | 0.38 |
| ▸ | LPAR5 | Q9H1C0 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | USP2 | O75604 | 1/20 | 0.37 |
| ▸ | GRM5 | P41594 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27664668 | 0.92 | POLB (0.43) | ALDH1A1NPC1RAB9ASMN1; SMN2POLB | |
| SCHEMBL5035881 | 0.91 | KMT2A (0.39) | ALDH1A1NPC1RAB9AHPGDLMNA | |
| SCHEMBL5034690 | 0.89 | CNR1 (0.40) | ALDH1A1NPC1RAB9APDE2AKDM4E | |
| SCHEMBL5032584 | 0.88 | HCRTR1 (0.41) | ALDH1A1NPC1RAB9ASMN1; SMN2HPGD | |
| SCHEMBL5032530 | 0.87 | HTR2C (0.43) | ALDH1A1NPSR1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL5034816 | 0.86 | RAB9A (0.37) | ALDH1A1NPC1RAB9AGAATSHR | |
| SCHEMBL5034814 | 0.86 | RAB9A (0.37) | ALDH1A1NPC1RAB9AGAATSHR | |
| SCHEMBL5032532 | 0.86 | NPC1 (0.37) | ALDH1A1NPC1RAB9AKDM4ETSHR | |
| SCHEMBL5035249 | 0.86 | LMNA (0.38) | NPC1RAB9ALMNAGRM5MAPT | |
| SCHEMBL5032648 | 0.86 | ALDH1A1 (0.48) | ALDH1A1NPSR1NPC1RAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1694673-B1 | THIAZOLE DERIVATES | HOFFMANN LA ROCHE (CH) | 2008-01-16 | — | — | EP | claimed |
| JP-2007513193-A | — | — | 2007-05-24 | — | — | JP | claimed |
| EP-1694673-A1 | NOVEL THIAZOLE DERIVATES | F.HOFFMANN-LA ROCHE AG (CH) | 2006-08-30 | — | — | EP | claimed |
| US-20050153962-A1 | Thiazole derivatives | HOFFMANN-LA ROCHE INC. | 2005-07-14 | — | — | US | claimed |
| WO-2005058887-A1 | NOVEL THIAZOLE DERIVATES | F. HOFFMANN-LA ROCHE AG (CH) | 2005-06-30 | — | — | WO | claimed |
| US-7371751-B2 | Thiazole derivatives | HOFFMANN-LA ROCHE INC. (US) | 2008-05-13 | — | — | US | disclosed |
| US-7371751-B2 | Thiazole derivatives | HOFFMANN-LA ROCHE INC. (US) | 2008-05-13 | — | — | US | disclosed |
| US-7371751-B2 | Thiazole derivatives | HOFFMANN-LA ROCHE INC. (US) | 2008-05-13 | — | — | US | disclosed |
| EP-1694673-B1 | THIAZOLE DERIVATES | HOFFMANN LA ROCHE (CH) | 2008-01-16 | — | — | EP | disclosed |
| EP-1694673-A1 | NOVEL THIAZOLE DERIVATES | F.HOFFMANN-LA ROCHE AG (CH) | 2006-08-30 | — | — | EP | disclosed |
| US-6960595-B2 | 5-6 to 5-7 Heterobicycles as factor Xa inhibitors | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2005-11-01 | — | — | US | disclosed |
| US-20050153962-A1 | Thiazole derivatives | HOFFMANN-LA ROCHE INC. | 2005-07-14 | — | — | US | disclosed |
| WO-2005058887-A1 | NOVEL THIAZOLE DERIVATES | F. HOFFMANN-LA ROCHE AG (CH) | 2005-06-30 | — | — | WO | disclosed |
| US-20040038980-A1 | Imidazo-heterobicycles as factor xa inhibitors | LAM PATRICK Y (US) | 2004-02-26 | — | — | US | disclosed |
| US-20030018023-A1 | 5-6 or 5-7 Heterobicycles as Factor Xa inhibitors | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2003-01-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040038980-A1 | Imidazo-heterobicycles as factor xa inhibitors | SERPINC1, SPINT2, TFPI | ALDH1A1 2464/4885NPSR1 1057/4885NPC1 2409/4885 |
| US-20030018023-A1 | 5-6 or 5-7 Heterobicycles as Factor Xa inhibitors | HABP2, SERPINC1, F7 | ALDH1A1 3452/4885NPSR1 1547/4885NPC1 3150/4885 |
| US-20050153962-A1 | Thiazole derivatives | CNR1, CNR2, GPR119 | ALDH1A1 473/4885NPSR1 39/4885NPC1 313/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.